Vyvanse (lisdexamfetamine)

VYVANSE (lisdexamfetamine dimesylate) – a central nervous system (CNS) stimulant commonly used to treat symptoms of attention deficit hyperactivity disorder (ADHD). Amphetamines block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extraneuronal space. The precise mechanism of action of how amphetamines and other CNS stimulants exert their clinical effect in ADHD is not known.

FDA approved uses: Vyvanse is indicated for the treatment of attention deficit hyperactivity disorder (ADHD).
Available dosage forms: Capsules -20, 30, 40, 50, 60 and 70 mg.

Usual dosage: The recommended starting dose of Vyvanse is 30mg once daily in the morning in patients ages 6 and above. Increase in increments of 10 or 20 mg at weekly intervals if needed. Maximum dose: 70 mg per day. Prior to treatment, assess for presence of cardiac disease.

Contraindications: Vyvanse (lisdexamfetamine dimesylate hydrochloride) is contraindicated in patients with known hypersensitivity to lisdexamfetamine dimesylate hydrochloride or to any excipients used in the formulation, and with monoamine oxidase (MAO) inhibitor, or within 14 days of the last MAO inhibitor dose.
Special warnings: CNS stimulants (amphetamines and methylphenidate-containing products) have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy.

Adverse reactions (side effects) of these medications: The most common side effects of include anorexia, anxiety, decreased appetite, decreased weight, diarrhea, dizziness, dry mouth, irritability, insomnia, nausea, upper abdominal pain, and vomiting. Other adverse events reported rash, fever, somnolence, tic. feeling jittery, agitation, increased blood pressure, hyperhidrosis, restlessness, dyspnea, increased heart rate, and tremors.

Common drug interactions: Ascorbic acid and other agents and conditions that acidify urine increase urinary excretion and decrease the half-life of amphetamine. Sodium bicarbonate and other agents and conditions that alkalinize urine decrease urinary excretion and extend the half-life of amphetamine. Do not administer Vyvanse concomitantly with monoamine oxidase inhibitors or within 14 days after discontinuing MAOI treatment. Concomitant use of MAOIs and CNS stimulants can cause hypertensive crisis. Potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure.

Special instructions for patients: Take this medication exactly as directed by physician. Consult medication guide before beginning this product at with each refill. Contact a healthcare provider immediately if you develop symptoms such as exertional chest pain, unexplained syncope, or other symptoms suggestive of cardiac disease. This medication may raise blood pressure and increase heart rate. Monitor and notify physician if these symptoms persist.

Full prescribing information may be found at the manufacturer‘s official website Vyvanse.com or at the U.S. Food and Drug Administration’s website at Vyvanse Info at Drugs@FDA

Tags: , , , ,

Comments are closed.